Lenalidomide-C5-NH2 is primarily utilized in the development of novel pharmaceutical compounds, particularly in the field of oncology. Its structure allows it to be a key intermediate in the synthesis of targeted cancer therapies, especially those designed to modulate the immune system and inhibit tumor growth. Researchers often employ it in the creation of proteolysis-targeting chimeras (PROTACs), which are innovative molecules that degrade specific proteins involved in cancer progression. Additionally, it is explored in the design of antibody-drug conjugates (ADCs), where it serves as a linker or payload to enhance the precision and efficacy of cancer treatments. Its application extends to experimental studies aimed at understanding and improving the therapeutic potential of immunomodulatory drugs.